1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Meloxicam
        1.2.3 Celecoxib
        1.2.4 Etoricoxib
        1.2.5 Imrecoxib
        1.2.6 Etodolac
        1.2.7 Parecoxib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Rheumatoid Arthritis
        1.3.3 Osteoarthritis
        1.3.4 Spondylosis Chronica Ankylopoietica
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Selective Cox-2 Inhibitors Market Perspective (2017-2028)
    2.2 Selective Cox-2 Inhibitors Growth Trends by Region
        2.2.1 Selective Cox-2 Inhibitors Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Selective Cox-2 Inhibitors Historic Market Size by Region (2017-2022)
        2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Region (2023-2028)
    2.3 Selective Cox-2 Inhibitors Market Dynamics
        2.3.1 Selective Cox-2 Inhibitors Industry Trends
        2.3.2 Selective Cox-2 Inhibitors Market Drivers
        2.3.3 Selective Cox-2 Inhibitors Market Challenges
        2.3.4 Selective Cox-2 Inhibitors Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Selective Cox-2 Inhibitors Players by Revenue
        3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2017-2022)
        3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2017-2022)
    3.2 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
    3.4 Global Selective Cox-2 Inhibitors Market Concentration Ratio
        3.4.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2021
    3.5 Selective Cox-2 Inhibitors Key Players Head office and Area Served
    3.6 Key Players Selective Cox-2 Inhibitors Product Solution and Service
    3.7 Date of Enter into Selective Cox-2 Inhibitors Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Selective Cox-2 Inhibitors Breakdown Data by Type
    4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2017-2022)
    4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2023-2028)
5 Selective Cox-2 Inhibitors Breakdown Data by Application
    5.1 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2017-2022)
    5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Selective Cox-2 Inhibitors Market Size (2017-2028)
    6.2 North America Selective Cox-2 Inhibitors Market Size by Type
        6.2.1 North America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        6.2.2 North America Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
        6.2.3 North America Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    6.3 North America Selective Cox-2 Inhibitors Market Size by Application
        6.3.1 North America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        6.3.2 North America Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
        6.3.3 North America Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    6.4 North America Selective Cox-2 Inhibitors Market Size by Country
        6.4.1 North America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        6.4.2 North America Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Selective Cox-2 Inhibitors Market Size (2017-2028)
    7.2 Europe Selective Cox-2 Inhibitors Market Size by Type
        7.2.1 Europe Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        7.2.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
        7.2.3 Europe Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    7.3 Europe Selective Cox-2 Inhibitors Market Size by Application
        7.3.1 Europe Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        7.3.2 Europe Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
        7.3.3 Europe Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    7.4 Europe Selective Cox-2 Inhibitors Market Size by Country
        7.4.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        7.4.2 Europe Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2017-2028)
    8.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type
        8.2.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application
        8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    8.4 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region
        8.4.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Selective Cox-2 Inhibitors Market Size (2017-2028)
    9.2 Latin America Selective Cox-2 Inhibitors Market Size by Type
        9.2.1 Latin America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        9.2.2 Latin America Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
        9.2.3 Latin America Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    9.3 Latin America Selective Cox-2 Inhibitors Market Size by Application
        9.3.1 Latin America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        9.3.2 Latin America Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
        9.3.3 Latin America Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    9.4 Latin America Selective Cox-2 Inhibitors Market Size by Country
        9.4.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        9.4.2 Latin America Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2017-2028)
    10.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type
        10.2.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Type (2017-2028)
    10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application
        10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Application (2017-2028)
    10.4 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country
        10.4.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Boehringer-Ingelheim
        11.1.1 Boehringer-Ingelheim Company Details
        11.1.2 Boehringer-Ingelheim Business Overview
        11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
        11.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.1.5 Boehringer-Ingelheim Recent Developments
    11.2 TerSera Therapeutics
        11.2.1 TerSera Therapeutics Company Details
        11.2.2 TerSera Therapeutics Business Overview
        11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
        11.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.2.5 TerSera Therapeutics Recent Developments
    11.3 Iroko Pharmaceuticals
        11.3.1 Iroko Pharmaceuticals Company Details
        11.3.2 Iroko Pharmaceuticals Business Overview
        11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.3.5 Iroko Pharmaceuticals Recent Developments
    11.4 Apotex
        11.4.1 Apotex Company Details
        11.4.2 Apotex Business Overview
        11.4.3 Apotex Selective Cox-2 Inhibitors Introduction
        11.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.4.5 Apotex Recent Developments
    11.5 Yung Shin Pharmaceutical
        11.5.1 Yung Shin Pharmaceutical Company Details
        11.5.2 Yung Shin Pharmaceutical Business Overview
        11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.5.5 Yung Shin Pharmaceutical Recent Developments
    11.6 Breckenridge Pharmaceutical
        11.6.1 Breckenridge Pharmaceutical Company Details
        11.6.2 Breckenridge Pharmaceutical Business Overview
        11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.6.5 Breckenridge Pharmaceutical Recent Developments
    11.7 Meda Pharmaceuticals
        11.7.1 Meda Pharmaceuticals Company Details
        11.7.2 Meda Pharmaceuticals Business Overview
        11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.7.5 Meda Pharmaceuticals Recent Developments
    11.8 Cipla
        11.8.1 Cipla Company Details
        11.8.2 Cipla Business Overview
        11.8.3 Cipla Selective Cox-2 Inhibitors Introduction
        11.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.8.5 Cipla Recent Developments
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.9.5 Glenmark Pharmaceuticals Recent Developments
    11.10 Teva
        11.10.1 Teva Company Details
        11.10.2 Teva Business Overview
        11.10.3 Teva Selective Cox-2 Inhibitors Introduction
        11.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.10.5 Teva Recent Developments
    11.11 PuraCap Pharmaceutical
        11.11.1 PuraCap Pharmaceutical Company Details
        11.11.2 PuraCap Pharmaceutical Business Overview
        11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.11.5 PuraCap Pharmaceutical Recent Developments
    11.12 Almirall Limited
        11.12.1 Almirall Limited Company Details
        11.12.2 Almirall Limited Business Overview
        11.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
        11.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.12.5 Almirall Limited Recent Developments
    11.13 Lupin Pharmaceuticals
        11.13.1 Lupin Pharmaceuticals Company Details
        11.13.2 Lupin Pharmaceuticals Business Overview
        11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.13.5 Lupin Pharmaceuticals Recent Developments
    11.14 Aurobindo Pharma
        11.14.1 Aurobindo Pharma Company Details
        11.14.2 Aurobindo Pharma Business Overview
        11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
        11.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.14.5 Aurobindo Pharma Recent Developments
    11.15 Pfizer
        11.15.1 Pfizer Company Details
        11.15.2 Pfizer Business Overview
        11.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
        11.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.15.5 Pfizer Recent Developments
    11.16 Mylan
        11.16.1 Mylan Company Details
        11.16.2 Mylan Business Overview
        11.16.3 Mylan Selective Cox-2 Inhibitors Introduction
        11.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.16.5 Mylan Recent Developments
    11.17 Takeda
        11.17.1 Takeda Company Details
        11.17.2 Takeda Business Overview
        11.17.3 Takeda Selective Cox-2 Inhibitors Introduction
        11.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.17.5 Takeda Recent Developments
    11.18 Bayer
        11.18.1 Bayer Company Details
        11.18.2 Bayer Business Overview
        11.18.3 Bayer Selective Cox-2 Inhibitors Introduction
        11.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.18.5 Bayer Recent Developments
    11.19 Novacap
        11.19.1 Novacap Company Details
        11.19.2 Novacap Business Overview
        11.19.3 Novacap Selective Cox-2 Inhibitors Introduction
        11.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.19.5 Novacap Recent Developments
    11.20 Abbott
        11.20.1 Abbott Company Details
        11.20.2 Abbott Business Overview
        11.20.3 Abbott Selective Cox-2 Inhibitors Introduction
        11.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.20.5 Abbott Recent Developments
    11.21 Geri-Care
        11.21.1 Geri-Care Company Details
        11.21.2 Geri-Care Business Overview
        11.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
        11.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.21.5 Geri-Care Recent Developments
    11.22 Perrigo
        11.22.1 Perrigo Company Details
        11.22.2 Perrigo Business Overview
        11.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
        11.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.22.5 Perrigo Recent Developments
    11.23 Kopran
        11.23.1 Kopran Company Details
        11.23.2 Kopran Business Overview
        11.23.3 Kopran Selective Cox-2 Inhibitors Introduction
        11.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.23.5 Kopran Recent Developments
    11.24 Merck
        11.24.1 Merck Company Details
        11.24.2 Merck Business Overview
        11.24.3 Merck Selective Cox-2 Inhibitors Introduction
        11.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.24.5 Merck Recent Developments
    11.25 Hengrui pharmaceutical
        11.25.1 Hengrui pharmaceutical Company Details
        11.25.2 Hengrui pharmaceutical Business Overview
        11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.25.5 Hengrui pharmaceutical Recent Developments
    11.26 Kelun Group
        11.26.1 Kelun Group Company Details
        11.26.2 Kelun Group Business Overview
        11.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
        11.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.26.5 Kelun Group Recent Developments
    11.27 Qilu Pharmaceutical
        11.27.1 Qilu Pharmaceutical Company Details
        11.27.2 Qilu Pharmaceutical Business Overview
        11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.27.5 Qilu Pharmaceutical Recent Developments
    11.28 Taro Pharmaceuticals 
        11.28.1 Taro Pharmaceuticals  Company Details
        11.28.2 Taro Pharmaceuticals  Business Overview
        11.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Introduction
        11.28.4 Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.28.5 Taro Pharmaceuticals  Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Meloxicam
    Table 3. Key Players of Celecoxib
    Table 4. Key Players of Etoricoxib
    Table 5. Key Players of Imrecoxib
    Table 6. Key Players of Etodolac
    Table 7. Key Players of Parecoxib
    Table 8. Key Players of Other
    Table 9. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 10. Global Selective Cox-2 Inhibitors Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 11. Global Selective Cox-2 Inhibitors Market Size by Region (2017-2022) & (US$ Million)
    Table 12. Global Selective Cox-2 Inhibitors Market Share by Region (2017-2022)
    Table 13. Global Selective Cox-2 Inhibitors Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 14. Global Selective Cox-2 Inhibitors Market Share by Region (2023-2028)
    Table 15. Selective Cox-2 Inhibitors Market Trends
    Table 16. Selective Cox-2 Inhibitors Market Drivers
    Table 17. Selective Cox-2 Inhibitors Market Challenges
    Table 18. Selective Cox-2 Inhibitors Market Restraints
    Table 19. Global Selective Cox-2 Inhibitors Revenue by Players (2017-2022) & (US$ Million)
    Table 20. Global Selective Cox-2 Inhibitors Revenue Share by Players (2017-2022)
    Table 21. Global Top Selective Cox-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2021)
    Table 22. Ranking of Global Top Selective Cox-2 Inhibitors Companies by Revenue (US$ Million) in 2021
    Table 23. Global 5 Largest Players Market Share by Selective Cox-2 Inhibitors Revenue (CR5 and HHI) & (2017-2022)
    Table 24. Key Players Headquarters and Area Served
    Table 25. Key Players Selective Cox-2 Inhibitors Product Solution and Service
    Table 26. Date of Enter into Selective Cox-2 Inhibitors Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 29. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2017-2022)
    Table 30. Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 31. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2023-2028)
    Table 32. Global Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 33. Global Selective Cox-2 Inhibitors Revenue Share by Application (2017-2022)
    Table 34. Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 35. Global Selective Cox-2 Inhibitors Revenue Share by Application (2023-2028)
    Table 36. North America Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 37. North America Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
    Table 38. North America Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 39. North America Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
    Table 40. North America Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
    Table 41. North America Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Europe Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 43. Europe Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
    Table 44. Europe Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 45. Europe Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
    Table 46. Europe Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
    Table 47. Europe Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
    Table 52. Asia Pacific Selective Cox-2 Inhibitors Market Size by Region (2017-2022) & (US$ Million)
    Table 53. Asia Pacific Selective Cox-2 Inhibitors Market Size by Region (2023-2028) & (US$ Million)
    Table 54. Latin America Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 55. Latin America Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
    Table 56. Latin America Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 57. Latin America Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
    Table 58. Latin America Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
    Table 59. Latin America Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Type (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Type (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Application (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Application (2023-2028) & (US$ Million)
    Table 64. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Country (2017-2022) & (US$ Million)
    Table 65. Middle East and Africa Selective Cox-2 Inhibitors Market Size by Country (2023-2028) & (US$ Million)
    Table 66. Boehringer-Ingelheim Company Details
    Table 67. Boehringer-Ingelheim Business Overview
    Table 68. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product
    Table 69. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 70. Boehringer-Ingelheim Recent Developments
    Table 71. TerSera Therapeutics Company Details
    Table 72. TerSera Therapeutics Business Overview
    Table 73. TerSera Therapeutics Selective Cox-2 Inhibitors Product
    Table 74. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 75. TerSera Therapeutics Recent Developments
    Table 76. Iroko Pharmaceuticals Company Details
    Table 77. Iroko Pharmaceuticals Business Overview
    Table 78. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 79. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 80. Iroko Pharmaceuticals Recent Developments
    Table 81. Apotex Company Details
    Table 82. Apotex Business Overview
    Table 83. Apotex Selective Cox-2 Inhibitors Product
    Table 84. Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 85. Apotex Recent Developments
    Table 86. Yung Shin Pharmaceutical Company Details
    Table 87. Yung Shin Pharmaceutical Business Overview
    Table 88. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 89. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 90. Yung Shin Pharmaceutical Recent Developments
    Table 91. Breckenridge Pharmaceutical Company Details
    Table 92. Breckenridge Pharmaceutical Business Overview
    Table 93. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 94. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 95. Breckenridge Pharmaceutical Recent Developments
    Table 96. Meda Pharmaceuticals Company Details
    Table 97. Meda Pharmaceuticals Business Overview
    Table 98. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 99. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 100. Meda Pharmaceuticals Recent Developments
    Table 101. Cipla Company Details
    Table 102. Cipla Business Overview
    Table 103. Cipla Selective Cox-2 Inhibitors Product
    Table 104. Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 105. Cipla Recent Developments
    Table 106. Glenmark Pharmaceuticals Company Details
    Table 107. Glenmark Pharmaceuticals Business Overview
    Table 108. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 109. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 110. Glenmark Pharmaceuticals Recent Developments
    Table 111. Teva Company Details
    Table 112. Teva Business Overview
    Table 113. Teva Selective Cox-2 Inhibitors Product
    Table 114. Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 115. Teva Recent Developments
    Table 116. PuraCap Pharmaceutical Company Details
    Table 117. PuraCap Pharmaceutical Business Overview
    Table 118. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 119. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 120. PuraCap Pharmaceutical Recent Developments
    Table 121. Almirall Limited Company Details
    Table 122. Almirall Limited Business Overview
    Table 123. Almirall Limited Selective Cox-2 Inhibitors Product
    Table 124. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 125. Almirall Limited Recent Developments
    Table 126. Lupin Pharmaceuticals Company Details
    Table 127. Lupin Pharmaceuticals Business Overview
    Table 128. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 129. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 130. Lupin Pharmaceuticals Recent Developments
    Table 131. Aurobindo Pharma Company Details
    Table 132. Aurobindo Pharma Business Overview
    Table 133. Aurobindo Pharma Selective Cox-2 Inhibitors Product
    Table 134. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 135. Aurobindo Pharma Recent Developments
    Table 136. Pfizer Company Details
    Table 137. Pfizer Business Overview
    Table 138. Pfizer Selective Cox-2 Inhibitors Product
    Table 139. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 140. Pfizer Recent Developments
    Table 141. Mylan Company Details
    Table 142. Mylan Business Overview
    Table 143. Mylan Selective Cox-2 Inhibitors Product
    Table 144. Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 145. Mylan Recent Developments
    Table 146. Takeda Company Details
    Table 147. Takeda Business Overview
    Table 148. Takeda Selective Cox-2 Inhibitors Product
    Table 149. Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 150. Takeda Recent Developments
    Table 151. Bayer Company Details
    Table 152. Bayer Business Overview
    Table 153. Bayer Selective Cox-2 Inhibitors Product
    Table 154. Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 155. Bayer Recent Developments
    Table 156. Novacap Company Details
    Table 157. Novacap Business Overview
    Table 158. Novacap Selective Cox-2 Inhibitors Product
    Table 159. Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 160. Novacap Recent Developments
    Table 161. Abbott Company Details
    Table 162. Abbott Business Overview
    Table 163. Abbott Selective Cox-2 Inhibitors Product
    Table 164. Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 165. Abbott Recent Developments
    Table 166. Geri-Care Company Details
    Table 167. Geri-Care Business Overview
    Table 168. Geri-Care Selective Cox-2 Inhibitors Product
    Table 169. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 170. Geri-Care Recent Developments
    Table 171. Perrigo Company Details
    Table 172. Perrigo Business Overview
    Table 173. Perrigo Selective Cox-2 Inhibitors Product
    Table 174. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 175. Perrigo Recent Developments
    Table 176. Kopran Company Details
    Table 177. Kopran Business Overview
    Table 178. Kopran Selective Cox-2 Inhibitors Product
    Table 179. Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 180. Kopran Recent Developments
    Table 181. Merck Company Details
    Table 182. Merck Business Overview
    Table 183. Merck Selective Cox-2 Inhibitors Product
    Table 184. Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 185. Merck Recent Developments
    Table 186. Hengrui pharmaceutical Company Details
    Table 187. Hengrui pharmaceutical Business Overview
    Table 188. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product
    Table 189. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 190. Hengrui pharmaceutical Recent Developments
    Table 191. Kelun Group Company Details
    Table 192. Kelun Group Business Overview
    Table 193. Kelun Group Selective Cox-2 Inhibitors Product
    Table 194. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 195. Kelun Group Recent Developments
    Table 196. Qilu Pharmaceutical Company Details
    Table 197. Qilu Pharmaceutical Business Overview
    Table 198. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 199. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 200. Qilu Pharmaceutical Recent Developments
    Table 201. Taro Pharmaceuticals  Company Details
    Table 202. Taro Pharmaceuticals  Business Overview
    Table 203. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product
    Table 204. Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2017-2022) & (US$ Million)
    Table 205. Taro Pharmaceuticals  Recent Developments
    Table 206. Research Programs/Design for This Report
    Table 207. Key Data Information from Secondary Sources
    Table 208. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2021 VS 2028
    Figure 2. Meloxicam Features
    Figure 3. Celecoxib Features
    Figure 4. Etoricoxib Features
    Figure 5. Imrecoxib Features
    Figure 6. Etodolac Features
    Figure 7. Parecoxib Features
    Figure 8. Other Features
    Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2021 VS 2028
    Figure 10. Rheumatoid Arthritis Case Studies
    Figure 11. Osteoarthritis Case Studies
    Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
    Figure 13. Other Case Studies
    Figure 14. Selective Cox-2 Inhibitors Report Years Considered
    Figure 15. Global Selective Cox-2 Inhibitors Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 16. Global Selective Cox-2 Inhibitors Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Selective Cox-2 Inhibitors Market Share by Region: 2021 VS 2028
    Figure 18. Global Selective Cox-2 Inhibitors Market Share by Players in 2021
    Figure 19. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2021)
    Figure 20. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2021
    Figure 21. North America Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
    Figure 22. North America Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
    Figure 23. North America Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
    Figure 24. North America Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
    Figure 25. United States Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Canada Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Europe Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
    Figure 28. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
    Figure 29. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
    Figure 30. Europe Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
    Figure 31. Germany Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. France Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. U.K. Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Italy Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Russia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Nordic Countries Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
    Figure 38. Asia Pacific Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
    Figure 39. Asia Pacific Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
    Figure 40. Asia Pacific Selective Cox-2 Inhibitors Market Size Share by Region (2017-2028)
    Figure 41. China Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. South Korea Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. India Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Australia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 47. Latin America Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
    Figure 48. Latin America Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
    Figure 49. Latin America Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
    Figure 50. Latin America Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
    Figure 51. Mexico Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Brazil Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Middle East & Africa Selective Cox-2 Inhibitors Market Size YoY (2017-2028) & (US$ Million)
    Figure 54. Middle East and Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2017-2028)
    Figure 55. Middle East and Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2017-2028)
    Figure 56. Middle East and Africa Selective Cox-2 Inhibitors Market Size Share by Country (2017-2028)
    Figure 57. Turkey Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. Saudi Arabia Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. UAE Selective Cox-2 Inhibitors Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 60. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 61. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 62. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 63. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 64. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 65. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 66. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 67. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 68. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 69. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 70. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 71. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 72. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 73. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 74. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 75. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 76. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 77. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 78. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 79. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 80. Geri-Care Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 81. Perrigo Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 82. Kopran Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 83. Merck Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 84. Hengrui pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 85. Kelun Group Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 86. Qilu Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 87. Taro Pharmaceuticals  Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2017-2022)
    Figure 88. Bottom-up and Top-down Approaches for This Report
    Figure 89. Data Triangulation
    Figure 90. Key Executives Interviewed